publication date: Mar. 1, 2019

Conversation with The Cancer Letter

CDC: HPV vaccine dramatically reduced HPV-related cervical precancers over 6 years

Nancy McClung_edit

Nancy McClung

Epidemic Intelligence Service Officer, CDC


The number of cases of HPV+ cervical precancers has dropped by 21 percent from 2008 to 2014, according to a survey by the Centers for Disease Control and Prevention.

The estimated number of all reported cases attributed to HPV 16/18 declined from 1,235 cases in 2008 to 819 cases in 2014. The study, which analyzed data from women age 18-39 years diagnosed with cervical intraepithelial neoplasia grades 2-3 or adenocarcinoma in situ (CIN2+) was published Feb. 21 in Cancer Epidemiology, Biomarkers & Prevention.

“The major takeaway from this study is that the HPV vaccine is working to reduce cervical disease in young women in the United States,” Nancy McClung, first author of the study, and Epidemic Intelligence Service Officer at CDC, said to The Cancer Letter.

As herd immunity grew, a decrease of 4 percent was observed in unvaccinated women.

“A decrease in HPV16/18-positive CIN2+ was also observed among unvaccinated women, suggesting for the first time, herd protection for CIN2+ in the United States,” the study said. “The decreasing trend in the proportion of HPV16/18-positive CIN2+ among 25–34-year olds is the first observation of vaccine impact in these older ages in the United States.”

The study reported that “since vaccine introduction, cervical precancer incidence has declined 56 percent among 18–20-year … Continue reading CDC: HPV vaccine dramatically reduced HPV-related cervical precancers over 6 years

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.